The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer
BRAFV600E mutations occur in 10% of colorectal cancer (CRC) cases, are associated with poor survival and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition. There is an unmet need to understand the biology of poor prognostic BRAFMT CRC. We have used differential gene expre...
Main Authors: | Forsythe, N, Refaat, A, Javadi, A, Khawaja, H, Weir, J, Emam, H, Allen, W, Burkamp, F, Popovici, V, Jithesh, P, Isella, C, LaBonte, M, Mills, I, Johnston, P, Van Schaeybroeck, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Association for Cancer Research
2018
|
Similar Items
-
Targeting mutant BRAF in colorectal cancer
by: Carroll David, et al.
Published: (2013-01-01) -
Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials
by: Seligmann, JF, et al.
Published: (2016) -
Current Advances in the Treatment of BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2020-02-01) -
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2021-11-01) -
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers
by: Suzanne Kazandjian, et al.
Published: (2024-01-01)